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Abstract
Background: Lung cancer is the leading cause of cancer death in the United States. Identifying factors associated
with stage of diagnosis can improve our understanding of biologic and behavioral pathways of lung cancer
development and detection. We used data from a prospective cohort study to evaluate associations of
demographic, health history, and health behaviors with early versus late stage at diagnosis of non-small cell lung
cancer (NSCLC).
Methods: We calculated odds ratios (ORs) for the association of patient-level characteristics with advanced stage of
diagnosis for NSCLC. The OR’s were then adjusted for age, gender, race/ethnicity, smoking status, income,
education, chronic obstructive pulmonary disease, and a comorbidity index.
Results: We identified 612 cases of NSCLC among 77,719 adults, aged 50 to 76 years from Washington State
recruited in 2000-2002, with followup through December 2007. In univariate analyses, subjects who quit smoking
<10 years (OR 2.56, 95% CI 1.17 - 5.60) and were college graduates (OR 1.67, 95% CI, 1.00 - 2.76) had increased risks
of being diagnosed with advanced stage NSCLC, compared to never smokers and non-college graduates,
respectively. Receipt of sigmoidoscopy/colonoscopy, compared to no receipt, was associated with a decreased risk
of advanced stage (OR 0.65, 95% CI, 0.43 - 0.99). The adjusted OR for receipt of sigmoidoscopy/colonoscopy was
0.55 (95% CI, 0.36 - 0.86). There was evidence that increasing the number of screening activities was associated
with a decreased risk of advanced stage NSCLC (P for trend = 0.049).
Conclusions: Smoking status, education, and a screening activity were associated with stage at diagnosis of
NSCLC. These results may guide future studies of the underlying mechanisms that influence how NSCLC is
detected and diagnosed.
Background
Lung cancer is the second most common cancer
amongst men and women and the leading cause of can-
cer-related mortality [1]. Lung cancer mortality is high
since it is often detected after development of late stage
disease [1]. Accordingly, there is substantial interest in
methods to prevent lung cancer, inhibit or slow down
its growth and progression, and to detect early stage
lung cancer through the use of imaging or biomarker
modalities [2,3].
Cancer is detected based on symptoms, incidental
findings, or active screening [4]. Accordingly, mechan-
isms that alter the development, perception, or reporting
of symptoms, alter the likelihood of finding cancer inci-
dentally, and/or alter the likelihood of screening may
impact the stage of diagnosis. Identifying individual fac-
tors associated with stage of diagnosis can improve our
understanding of biologic and behavioral pathways of
lung cancer development and detection.
Individual predictors of lung cancer diagnosis stage
have not been well studied. We used the data from a
prospective cohort study (the Vitamins and Lifestyle
(VITAL) study) to evaluate associations of demographic,
health history, and health behaviors with early versus
late stage at diagnosis of non-small cell lung cancer
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screening is ongoing [5], we hypothesized that other
screening behaviors might be associated with a
decreased risk of an advanced stage at diagnosis.
MethodsSubjects
The VITAL study is a prospective cohort of community-
dwelling adults [6]. Women and men were eligible if
they were aged 50 to 76 and lived in the area covered
by the Seattle-Puget Sound Surveillance, Epidemiology,
and End Results (SEER) cancer registry. Using a com-
mercial list, we mailed 364,418 questionnaires from
October 2000 to December 2002. 77,719 (21.3%) partici-
pants returned questionnaires and passed eligibility and
quality control checks. Baseline data were obtained from
as e x - s p e c i f i c2 4 - p a g es e l f - a dministered questionnaire
that included items on medication use, diet, medical his-
tory, personal characteristics, and cancer risk factors.
The Institutional Review Board of the Fred Hutchinson
Cancer Research Center approved the protocol.
Participants were followed for lung cancer occurring
from baseline through December 31, 2007, by linking
the cohort to the Seattle-Puget Sound SEER registry.
Cases and information on tumor characteristics, includ-
ing histology and stage at diagnosis, are ascertained
through all hospitals in the area, offices of pathologists,
oncologists, and radiotherapists, and from state death
certificates. The SEER registry has been shown to have
accurate and complete data collection [7] and is reliable
for lung cancer histology [8]. If a subject had multiple
diagnoses of lung cancer, we used the stage of the first
primary diagnosis.
We excluded participants with a previous diagnosis of
lung cancer reported at baseline (n = 376) or for whom
this datum was missing (n = 211). We also excluded
subjects whose lung cancer was identified on a death
certificate only or whose lung cancer morphology was
classified as lymphoma (n = 10). We elected to only
include cases of NSCLC since growth rates, staging, and
symptomatology markedly differ from small cell lung
cancer. After these exclusions, 612 participants devel-
oped NSCLC within a mean followup time of 5.9 years
(SD 1.2 years).Outcome Assessment: Stage at Diagnosis
Based on SEER data, we dichotomized stage at diagnosis
into in-situ and local (early stage) versus regional, dis-
tant, or unknown stage (advanced stage). Unknown
stage was combined with the latter group because it has
a comparable survival rate [1].Covariates
Sociodemographic & Health History
Subjects reported demographic and socioeconomic fac-
tors that included age, race/ethnicity, marital status, and
education. Self-report of physician-diagnosed chronic
obstructive pulmonary disease (COPD), including
emphysema and chronic bronchitis, and previous history
of cancer were recorded. We categorized family history
of lung cancer as none or at least one first degree relative
with lung cancer. A comorbidity scale was created based
on self-report of the following conditions, categorized as
yes or no for each response: coronary artery disease,
heart failure, stroke, chronic pulmonary disease, rheuma-
toid arthritis, cirrhosis or other chronic liver disease, kid-
ney disease (other than kidney stones), diabetes, and
history of cancer other than non-melanotic skin cancer.
Subjects were asked detailed questions about their
exercise habits. Exercise is calculated as usual metabolic
equivalent of task (MET) hours per week for each activ-
ity averaged over the previous 10 years as follows: [Fre-
quency of activity per week * minutes per session *
years in the past 10 * MET for that activity] / [(60 min-
utes/hour) * 10 years] [9]. We then summed the MET
hours for all activities to calculate total 10-year average
MET hours per week. We categorized exercise into
quartiles. Body mass index (BMI) was calculated from
the respondent’s self-reported current weight and
height, measured as kg/m
2, and categorized. Daily ser-
vings of fruit were assessed by a food frequency ques-
tionnaire (FFQ) that was an adaptation of FFQ’s
developed for the Women’s Health Initiative and other
studies [10-12], with the addition of highly supplemen-
ted foods. The measurement properties of earlier ver-
sions of this questionnaire have been published [10].
Tobacco
Smokers were defined as individuals who smoked at
least one cigarette per day for at least a year. Smoking
status was classified as never, current, quit 10 years or
more or quit less than 10 years ago, at the date of ques-
tionnaire completion. Duration of smoking was esti-
mated by the reported number of years smoked,
intensity by the usual number of cigarettes smoked per
day, and pack-years was computed as years smoked ×
cigarettes per day/20.
Screening Activities
All subjects were asked if they had a sigmoidoscopy or
colonoscopy in the ten years prior to baseline. Men
reported if they had a prostate specific antigen (PSA)
test in the two years prior to baseline. Women reported
if they had a mammogram in the two years prior to
baseline.Statistical Analysis
All statistical analyses were performed using Stata SE-11
(StataCorp, College Station, TX). For the univariate ana-
lyses, the association between each factor and early ver-
sus advanced stage at diagnosis was measured through
logistic regression using robust standard errors. To eval-
uate our primary hypothesis that screening activities
would be associated with stage at diagnosis, we used
multivariable adjusted logistic regression using robust
standard errors. A priori, we decided to adjust for age at
baseline (continuous), gender, smoking status (never,
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income (classified as greater or less than $40,000/year
and missing), education (dichotomized as greater or less
than college graduate), race/ethnicity (dichotomized as
white versus other), comorbidity (modeled continu-
ously), and self-reported COPD (dichotomized as yes
versus no). Overall, there was less than 5% missing
information for all variables except income (21% missing
this information) and BMI (6% missing this informa-
tion). P values less than 0.05 were considered statisti-
cally significant.
We evaluated whether other factors individually con-
founded the association of screening activities with
NSCLC stage at diagnosis in the adjusted model. These
included: years of smoking, packyears, history of cancer,
exercise, BMI, marital status, and servings of fruit. None
changed the point estimates of the screening activity
variables by more than 10% or the 5% level of signifi-
cance so they were not included in the final model. We
performed sensitivity analyses by not including in-situ
and unknown stages in the outcome. As not including
these subjects in the screening analyses did not substan-
tively change the OR’s, we decided to include all stages
in the final model.
We examined whether the association between sig-
moidoscopy/colonoscopy receipt and NSCLC stage at
diagnosis differed by age, sex, and smoking status. These
models were adjusted as above with the exception of not
including age, sex, or smoking status, respectively, in the
stratified models. Since there were few never smokers
who developed lung cancer, we did not include this
group in the stratified smoking status analyses. Likeli-
hood ratio tests were conducted to assess the interaction
between sigmoidoscopy/colonoscopy and the subgroups.
P values for interaction were obtained to compare the
fit of the models with the interaction terms and without
them.Role of the Funding Source
This work was completed with grant support from the
CHEST Foundation of the American College of Chest
Physicians and the LUNGevity Foundation to C.S. This
work was also supported by the National Institutes of
Health [K05CA154337 to EW]. Drs. Slatore, Au, and
Deffebach were supported by the Department of Veter-
ans Affairs. This study is the result of work supported
by resources from the Portland VA Medical Center,
Portland, OR, and VA Puget Sound Health Care System,
Seattle, Washington. The study sponsors had no role in
the conduct of the study, in the collection, management,
analysis, or interpretation of data, or in the preparation,
review, or approval of the manuscript.
Results
Of the 612 cases of NSCLC, there were 280 cases of
adenocarcinoma (45.6%), 137 of squamous cell (22.4%),
18 of large cell (2.9%) and 177 of NSCLC, not otherwise
specified (28.9%). One subject (0.2%) was diagnosed
with an in situ stage at diagnosis, 131 (21.4%) local, 159
(26.0%) regional, 311 (50.8%) distant, and 10 (1.6%) had
an unknown stage.
When stratified by the stage at diagnosis, subjects
were similar in terms of age, race/ethnicity, smoking
duration/intensity, and history of cancer (Table 1).
Women and never smokers were less likely to be diag-
nosed with advanced stage. Former smokers who had
quit < 10 years were more often diagnosed with
advanced stage disease. College graduates were more
often diagnosed with advanced stage disease.
In the univariate analyses of the association of
potential factors with stage at diagnosis, subjects who
quit smoking <10 years (OR 2.56, 95% CI 1.17 - 5.60,
P = 0.019) and were college graduates (OR 1.66, 95% CI,
1.00 - 2.76, P = 0.048) had increased risks of being
diagnosed with advanced stage NSCLC, compared to
never smokers and non-college graduates, respectively
(Table 2). Receipt of sigmoidoscopy/colonoscopy (OR
0.65, 95% CI, 0.43 - 0.99, P = 0.043) was associated with
a decreased risk of advanced stage. Women were less
likely to be diagnosed with advanced stage (OR 0.68,
95% CI, 0.46 - 1.01, P = 0.053) though this association
was not significant.
We then examined the adjusted associations between
screening activities and stage at diagnosis (Table 3).
Receipt of sigmoidoscopy/colonoscopy was associated
with a decreased risk of being diagnosed with advanced
NSCLC (OR 0.55, 95% CI, 0.36 - 0.86, P < 0.01). Neither
PSA testing or mammography were associated with
stage at diagnosis. There was evidence that increasing
the number of screening activities was associated with a
decreased risk of advanced stage NSCLC (P for trend =
0.049).
We stratified the results of the sigmoidoscopy/colono-
scopy receipt and the stage at diagnosis associations by
age, gender, and smoking status (Table 4). There was
no evidence of effect modification for any of these
variables.
Discussion
This study found few demographic or socioeconomic
factors, health history, or health behaviors that were
associated with stage of diagnosis of non-small cell lung
cancer. Subjects who quit smoking <10 years and were
college graduates had increased risks of being diagnosed
with advanced stage NSCLC, compared to never smo-
kers and non-college graduates, respectively, whereas
sigmoidoscopy/colonoscopy receipt was associated with
a decreased risk. These associations should not be con-
strued as causal but may be important factors in the
development and detection of NSCLC.
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findings, or active screening and differences in stage at
diagnosis must operate via one or more of these
mechanisms [4]. In terms of symptoms, individuals may
d e l a yc a r ed e s p i t et h ep r e s e n c eo fs y m p t o m sa n d
present with advanced stages. Patients and clinicians
may delay symptomatic care for several reasons that
include health beliefs, limited access to healthcare, and/
or competing causes (e.g. attributing a cough in a smo-
ker to a benign cause). Also, factors that alter symptoms
for a particular stage could be associated with a differen-
tial stage at diagnosis (e.g. causing hemoptysis at an ear-
lier stage). Second, lung cancer is commonly found
incidentally on imaging studies [13]. Individuals with
decreased access to care may have fewer opportunities
to have asymptomatic, early stage tumors discovered
incidentally [14-17]. Comorbid diseases might also alter
the likelihood of incidental findings (e.g. a patient with
congestive heart failure is found to have an incidental
early stage tumor on a chest x-ray). A third factor is
active screening to identify asymptomatic cases.
Stage at diagnosis is a strong predictor of lung cancer
mortality [18] so identifying individual factors associated
with stage at diagnosis is important for several reasons.
First, identification may aid the development of disease
progression biomarkers through better understanding of
potential confounders [19]. Second, these factors may be
in the causal pathway for previously studied factors,
including race/ethnicity [16], census tract-level socioeco-
nomic status [14], rural versus urban location [15], and
insurance status [17], that have been associated with
lung cancer care disparities. Finally, it is likely that some
lung cancers grow too slowly to cause death [20-22].
Understanding factors associated with slow-growing
tumors, those with a higher chance of being found inci-
dentally at earlier stages, may aid research into underly-
ing mechanisms of tumor growth and development.
It is intriguing that a screening behavior was asso-
ciated with lower risk of an advanced stage at diagnosis
after adjusting for many potential confounders such as
access to care variables, comorbid diseases, and other
health behaviors. In addition, we compared in-situ and
local disease versus advanced disease; local stages are
rarely symptomatic [21] so factors that are mediated by
symptoms are unlikely to explain our findings. Smoking
status has not been evaluated in terms of its association
with stage of diagnosis but a recent study from Sweden
did not find an association with education status [23].
Patients who received a sigmoidoscopy/colonoscopy as
of 2002, and their clinicians, may have been “early adop-
ters” of screening as there was no solid evidence of its
benefit for preventing colon cancer mortality at that
time [24]. At the time of questionnaire administration
lung cancer screening was not recommended [25]. Com-
puted tomography (CT) may soon have a role in early
detection based on a preliminary report from the
National Lung Cancer Screening Trial that reports to
show a 20% decrease in lung cancer mortality in the
screened group [26]. Even before the results of this
study became available, some experts and advocacy
Table 1 Characteristics of cohort with non-small cell lung













Age (years) 67.0 (6.5) 67.0 (6.5)
Women 70 (53.0%) 209 (43.5%)
Non-White Race/Ethnicity 6 (4.6%) 27 (5.6%)
Smoking
Years of Smoking (years)* 32.4 (15.0) 33.8 (13.6)
Pack Years (years)* 40.3 (26.8) 44.3 (28.5)
Smoking Status
Never smoker 16 (12.1%) 32 (6.7%)
Current smoker 39 (29.6%) 141 (29.4%)
Former, Quit <10 yr 18 (13.6%) 92 (19.2%)
Former, Quit ≥10 yr 58 (43.9%) 211 (44.0%)
Socioeconomic
College Graduate or Higher 22 (16.7%) 121 (25.2%)
Income > $40,000/year 48 (36.4%) 189 (39.4%)
Currently Married/Partner 94 (71.2%) 327 (68.1%)
Medical History
COPD 23 (17.4%) 70 (14.6%)
History of Cancer 28 (21.2%) 102 (21.3%)
Family History Lung Cancer** 30 (22.7%) 89 (18.5%)
Comorbid Disease***
(1 or more)
74 (56.1%) 273 (56.9%)
Exercise (Highest Quartile)**** 22 (16.7%) 89 (18.5%)
BMI Category (kg/m
2)
Normal (18.5 - 24.9) 41 (31.1%) 164 (34.2%)
Underweight (<18.5) 4 (3.0%) 8 (1.7%)
Overweight (25 - 29.9) 55 (41.7%) 191 (39.8%)
Obese (≥30) 23 (17.4%) 89 (18.5%)
Screening Activities
Sigmoidoscopy/Colonoscopy 89 (67.4%) 275 (57.3%)
PSA (men only) 45 (72.6%) 187 (69.0%)
Mammogram (women only) 61 (87.1%) 191 (91.4%)
Screening (at least one
screening study)
118 (89.4%) 419 (87.3%)
Note: percentages are of total and may not sum to 100% secondary to
rounding and missing information
Abbreviations
BMI: Body Mass Index
COPD: Chronic Obstructive Pulmonary Disease
*among current or former smokers
** ≥11
st degree relative with lung cancer
***See definition in text
**** usual MET hours per week for each activity averaged over the previous
10 years
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utility of screening with their clinicians [27-29]. Similar
to the widespread adoption of prostate cancer screening
prior to evidence of its benefit [30,31], lung cancer
screening was advocated by some groups without
knowledge of its risks and benefits [32]. Patients may
currently undergo CT screening for lung cancer based
on their own or clinician beliefs about its efficacy
[5,33,34] and our results raise this possibility as well.
Understanding screening behaviors prior to the
implementation of widespread recommendations for CT
screening will assist evaluation of its implementation.
Our study has several strengths. We used a large, pro-
spective, population-based cohort study design. We con-
trolled for comorbid disease and factors associated with
access to care. Although we were unable to directly
adjust for insurance status, we adjusted for age in the
primary analysis and did not observe effect modification
for subjects over and under age 65, the age where there
is essentially universal coverage through Medicare.
Finally, the SEER database is complete and accurate, so
there is minimal risk of outcome misclassification.
Table 2 Univariate Odds Ratios (OR’s) for associations






Age (per year) 1.00 (0.98 - 1.03)
Women 0.68 (0.46 - 1.01)
Non-White Race/Ethnicity 1.24 (0.50 - 3.07)
Smoking
Years of Smoking (10 year increments)* 1.07 (0.93 - 1.23)
Pack Years (10 year increments)* 1.05 (0.98 - 1.13)
Smoking Status
Never smoker Ref
Current smoker 1.81 (0.90 - 3.63)
Former, Quit <10 yr 2.56 (1.17 - 5.60)
Former, Quit ≥10 yr 1.82 (0.93 - 3.55)
Socioeconomic
College Graduate or Higher 1.66 (1.00 - 2.76)
Income >$40,000/year 1.04 (0.67 - 1.62)
Currently Married or with Partner 0.77 (0.49 - 1.21)
Medical History
COPD 0.81 (0.48 - 1.35)
History of Cancer 1.00 (0.62 - 1.60)
Family History Lung Cancer** 0.79 (0.49 - 1.26)
Comorbid Disease*** (1 or more) 1.03 (0.69 - 1.52)
Exercise (Highest Quartile)**** 1.15 (0.69 - 1.93)
BMI Category (kg/m
2)
Normal (18.5 - 24.9) Ref
Underweight (<18.5) 0.50 (0.14 - 1.74)
Overweight (25 - 29.9) 0.87 (0.55 - 1.37)
Obese (≥30) 0.97 (0.55 - 1.72)
Missing 0.78 (0.34 - 1.78)
Screening Activities
Sigmoidoscopy/Colonoscopy 0.65 (0.43 - 0.99)
PSA (men only) 0.93 (0.50 - 1.73)
Mammogram (women only) 1.47 (0.61 - 3.59)
Screening (at least one screening study) 0.81 (0.43 - 1.53)
*among current or former smokers
** ≥11
st degree relative with lung cancer
***See definition in text
**** usual MET hours per week for each activity averaged over the previous
10 years
Table 3 Adjusted Odds Ratios (OR’s) for association of
screening activities with advanced stage at diagnosis of





Sigmoidoscopy/Colonoscopy 0.55 (0.36 - 0.86)
PSA 0.93 (0.50 - 1.74)
Mammogram 1.55 (0.55 - 4.39)
Number of Screening Activities
One 1.00 (0.48 - 2.07)
Two 0.62 (0.31 - 1.26)
P for trend 0.049
*Adjusted for age, gender, smoking status, income (included missing as a
category), education, race/ethnicity, comorbidity, & self-reported COPD
Table 4 Adjusted Odds Ratios (OR’s) for association of
sigmoidoscopy/colonoscopy receipt with advanced stage
at diagnosis of non-small lung cancer, stratified by age,





Age <65 0.70 (0.32 - 1.55)
Age ≥65 0.53 (0.30 - 0.94)
P for interaction 0.68
Gender**
Women 0.59 (0.31 - 1.14)
Men 0.52 (0.27 - 1.00)
P for interaction 0.63
Smoking Status***
Current smoker 0.65 (0.30 - 1.42)
Former, Quit <10 yr 0.19 (0.04 - 0.87)
Former, Quit ≥10 yr 0.56 (0.28 - 1.16)
P for interaction 0.46
*Adjusted for gender, smoking status, income (included missing as a
category), education, race/ethnicity, comorbidity, & self-reported emphysema
**Adjusted for age, smoking status, income (included missing as a category),
education, race/ethnicity, comorbidity, & self-reported emphysema
***Adjusted for age, gender, income (included missing as a category),
education, race/ethnicity, comorbidity, & self-reported COPD
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care and comorbid disease may influence our findings. In
addition, there are other limitations of this study. First,
the baseline survey did not discriminate between sigmoi-
doscopy/colonoscopy performed for colon cancer screen-
ing or symptoms. While it is likely most studies were
performed for screening, there is undoubtedly exposure
misclassification that likely attenuates the results. The
findings of this study may not be generalizable to other
populations since the VITAL cohort includes fewer smo-
kers, is predominantly white, and is more highly educated
than the general US population. However, although the
response rate to the survey was only 21%, it is unlikely
that selection bias could have affected our results because
in a prospective design, subjects cannot participate jointly
based on exposure and future (unknown) disease status.
Conclusion
This study identifies several individual factors associated
with stage at diagnosis of NSCLC, including an associa-
tion between a screening activity and a lower risk of a
diagnosis of advanced stage. This finding does not pro-
vide direct evidence that lung cancer screening is occur-
ring though it raises that possibility. Our results may
inform studies of healthcare disparities among patients
with lung cancer. Furthermore, these results may
prompt future studies of patient and clinician behaviors
that may influence stage at diagnosis.
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